{"id":"W2594051854","doi":"10.1016/j.ctarc.2017.02.005","title":"Challenging the Paradigm: EGFR wild-type benefit from an EGFR inhibitor in NSCLC","year":2017,"lang":"en","type":"article","venue":"Cancer Treatment and Research Communications","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia Hospital; BC Research (Canada); BC Cancer Agency","funders":"Boehringer Ingelheim; AstraZeneca","keywords":"Afatinib; Erlotinib; Gefitinib; Epidermal growth factor receptor; Lung cancer; Medicine; Erlotinib Hydrochloride; Oncology; EGFR inhibitors; Tyrosine kinase; Internal medicine; Cancer research; Cancer; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01019076,0.0003810846,0.001514713,0.0005646241,0.0006965752,0.003027762,0.001102496,0.00312794,0.005566643],"category_scores_gemma":[0.0197859,0.0002187199,0.001113398,0.0004814303,0.002499845,0.007011828,0.001568778,0.009335375,0.0009900465],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00251577,"about_ca_system_score_gemma":0.00392907,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00155614,"about_ca_topic_score_gemma":0.004226152,"domain_scores_codex":[0.9966055,0.002106942,0.0002630994,0.0003320497,0.0004853696,0.0002069657],"domain_scores_gemma":[0.9880597,0.009179677,0.0008526574,0.0003375254,0.0007074311,0.0008630086],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.006998064,0.0006043493,0.00905289,0.001770766,0.0008807674,0.0007043747,0.0003536816,0.005554936,0.00403581,0.2100588,0.1367115,0.623274],"study_design_scores_gemma":[0.002173044,0.003205966,0.01336155,0.002900791,0.001285063,0.001492348,0.001040398,0.00719467,0.001963185,0.7641459,0.2010703,0.0001667516],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.02683888,0.08334104,0.004380349,0.8657696,0.005263218,0.0000351626,0.0004655785,0.00005262788,0.0138535],"genre_scores_gemma":[0.5681118,0.08627092,0.006095416,0.2872397,0.04731706,0.0001446199,0.0003892452,0.0001098627,0.004321455],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.01019076,"threshold_uncertainty_score":0.05389452,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1682299182936018,"score_gpt":0.4979343324553248,"score_spread":0.329704414161723,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}